前列腺特异性抗原密度预测临床显著前列腺癌:按种族和体重指数分层的最佳截点
该研究纳入2162例血清PSA 4-10 ng/ml且接受前列腺活检的男性(56%为非裔美国人),比较PSA与PSA密度预测临床显著前列腺癌(GG≥2)的AUC,并计算PSA密度截点0.05-0.15 ng/ml/cc的阴性预测值。结果显示PSA密度将AUC从0.58提升至0.68,截点<0.08 ng/ml/cc对GG≥2的阴性预测值为96%,且在不同种族和BMI间基本一致。
要点
- PSA 4-10 ng/ml男性中,PSA密度<0.08 ng/ml/cc对GG≥2前列腺癌的阴性预测值为96%。
- PSA密度预测显著癌的AUC为0.68,优于PSA的0.58。
- PSA密度<0.08的阴性预测值在不同种族和BMI间基本不变。
核心结论
- 无论种族或BMI,PSA 4-10 ng/ml且PSA密度<0.08 ng/ml/cc的男性不太可能患有GG≥2前列腺癌。
研究设计与样本
- 回顾性分析2162例血清PSA 4-10 ng/ml接受前列腺活检的男性,其中56%为非裔美国人。
主要发现
- 中位PSA为5.6 ng/ml(IQR 4.8-7),中位PSA密度为0.15 ng/ml/cc(IQR 0.1-0.22)。
- PSA密度预测显著癌的AUC为0.68 vs PSA的0.58,预测任何癌的AUC为0.69 vs 0.55(均p<0.001)。
- PSA密度截点<0.08 ng/ml/cc对GG≥2的阴性预测值为96%,且在不同种族和BMI间基本不变。
关键数值与推荐
- PSA密度截点<0.08 ng/ml/cc对GG≥2前列腺癌的阴性预测值为96%。
临床怎么用
- PSA 4-10 ng/ml男性若PSA密度<0.08 ng/ml/cc,可考虑避免前列腺活检以减少过度检测和并发症。
局限性
- 结论需外部验证后才能推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the predictive value of prostate specific antigen density to detect clinically significant prostate cancer, defined as prostate cancer grade group 2 or greater, in a series of men undergoing prostate biopsy with prostate specific antigen 4 to 10 ng/ml. We sought to define an optimum cutoff point for prostate specific antigen density and assess how race and body mass index affects prostate specific antigen density performance. MATERIALS AND METHODS: We analyzed data on 2,162 men, of whom 56% were African American, with serum prostate specific antigen 4 to 10 ng/ml who underwent prostate biopsy. We compared the AUC between prostate specific antigen and prostate specific antigen density to predict clinically significant and any prostate cancer vs no cancer. We calculated the negative predictive value of prostate specific antigen density cutoff points ranging from 0.05 to 0.15 by every 0.01 step. We a priori defined the optimal cutoff point of prostate specific antigen density as a negative predictive value of 95% and tested whether the cutoff was sensitive to body mass index and race by comparing the negative predictive value across strata. RESULTS: Median prostate specific antigen was 5.6 ng/ml (IQR 4.8-7) and median prostate specific antigen density was 0.15 ng/ml/cc (IQR 0.1-0.22). Prostate specific antigen density improved the performance of prostate specific antigen to detect significant cancer (AUC 0.58 to 0.68) and any cancer (AUC 0.55 to 0.69, each p <0.001). We identified a prostate specific antigen density cutoff point of less than 0.08 ng/ml/cc with a 96% negative predictive value for grade group 2 or greater. This was largely unchanged among different races and body mass indexes. CONCLUSIONS: Regardless of race or body mass index men with prostate specific antigen density less than 0.08 were unlikely to harbor grade group 2 or greater disease when prostate specific antigen was 4 to 10 ng/ml. If validated, prostate specific antigen density is a simple inexpensive and available tool that can be used to identify men who can likely forego prostate biopsies, thus reducing the over detection and morbidity of unnecessary biopsies.
引用
- Aminsharifi A, Howard L, Wu Y, et al. Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. J Urol. 2018. PMID: 29758219. doi:10.1016/j.juro.2018.05.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。